SCHEMBL3010185

SCHEMBL3010185

COc1cc(OC)cc(-c2csc(N3CCC(S(=O)(=O)c4cc(Cl)cc(Cl)c4)CC3)n2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
MAPT P10636 12/20 0.46
HSD17B10 Q99714 3/20 0.46
USP2 O75604 1/20 0.46
RECQL P46063 1/20 0.46
ALDH1A1 P00352 9/20 0.44
MAPK1 P28482 6/20 0.44
MEN1 O00255 6/20 0.44
KMT2A Q03164 6/20 0.44
LMNA P02545 5/20 0.44
GAA P10253 3/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TP53 P04637 2/20 0.44
TSHR P16473 1/20 0.44
NPC1 O15118 2/20 0.44
HPGD P15428 1/20 0.43
HTT P42858 3/20 0.42
ALOX12 P18054 1/20 0.42
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007710 0.92 MAPT (0.49) RAB9ASMN1; SMN2MAPTHSD17B10USP2
SCHEMBL3011703 0.91 RAB9A (0.50) RAB9ASMN1; SMN2MAPTHSD17B10USP2
SCHEMBL2998531 0.91 SMN1; SMN2 (0.59) RAB9ASMN1; SMN2MAPTHSD17B10USP2
SCHEMBL3019225 0.90 MAPT (0.59) RAB9ASMN1; SMN2MAPTHSD17B10USP2
SCHEMBL2999860 0.89 SMN1; SMN2 (0.51) RAB9ASMN1; SMN2MAPTALDH1A1MAPK1
SCHEMBL3012044 0.89 SMN1; SMN2 (0.54) RAB9ASMN1; SMN2MAPTHSD17B10USP2
SCHEMBL3012347 0.89 SMN1; SMN2 (0.56) RAB9ASMN1; SMN2MAPTHSD17B10USP2
SCHEMBL3003694 0.88 MAPT (0.50) RAB9ASMN1; SMN2MAPTHSD17B10USP2
SCHEMBL3017534 0.88 MAPK1 (0.58) RAB9ASMN1; SMN2MAPTHSD17B10USP2
SCHEMBL3018971 0.88 MAPT (0.52) RAB9ASMN1; SMN2MAPTHSD17B10USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885SMN1; SMN2 1/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.